Journal of Cancer Research and Cellular Interventions (JCCRCI)

OLITES PUBLISHERS
A Global Approach For Research

Open Access

Short Communication

Reframing Urothelial Carcinoma: From Surface Malignancy to Systemic Ecosystem Disease

Krokidis D, Ravera T, Schott Y, Jovanovic E, Blinderman T, Kaufman R
Department of Family Medicine, Gil Medical Center, Republic of Korea
*** Corresponding Author**: Ravera T, Department of Family Medicine, Gil Medical Center, Republic of Korea
Citation: Ravera T (2025). Reframing Urothelial Carcinoma: From Surface Malignancy to Systemic Ecosystem Disease V1(3)

Received date: November21, 2025: **Accepted date**: November 29, 2025: **Published date**: December 05,2025
Keywords: immunotherapeutic strategies, ecosystem disease, immune surveillance, single-target therapies, immunotherapy

Abstract

Urothelial carcinoma (UC), traditionally viewed as a malignancy confined to the epithelial lining of the urinary tract, is increasingly recognized as a complex, systemic disease influenced by dynamic interactions between tumor cells, the microenvironment, immune modulation, and metabolic rewiring. This article proposes a new perspective that conceptualizes UC not merely as a localized epithelial disorder but as an evolving ecosystem shaped by genetic heterogeneity, environmental exposures, and host responses. Emerging insights into tumor plasticity, immune evasion, and molecular subtypes have redefined diagnostic and therapeutic paradigms. By integrating multi-omics data, liquid biopsy innovations, and immunotherapeutic strategies, this perspective highlights the need for a shift toward personalized, adaptive management. Understanding UC as a systemic and adaptive disease opens avenues for earlier detection, improved prognostication, and more effective, individualized treatment strategies.

Introduction

Urothelial carcinoma is one of the most common malignancies affecting the urinary system, predominantly arising in the bladder but also occurring in the renal pelvis, ureters, and urethra. Historically, its classification and treatment have been guided by histopathological grading and staging. However, recurrence, progression, and therapeutic resistance remain major clinical challenges

A growing body of evidence suggests that UC cannot be fully understood through a purely anatomical or histological lens. Instead, it should be viewed as a biologically dynamic and systemically influenced disease. This article introduces a novel conceptual framework—considering UC as an "ecosystem disease"—to better capture its complexity.

The Ecosystem Model of Urothelial Carcinoma

Tumor Heterogeneity as Ecological Diversity

Urothelial carcinoma exhibits significant intra tumoral and inter-tumoral heterogeneity. Distinct molecular subtypes (e.g., luminal, basal neuroendocrine-like) coexist within and across tumors. This diversity resembles ecological niches, where different cellular populations adapt to selective pressures such as hypoxia, immune surveillance, and therapy

ecological niches, where different cellular populations adapt to selective pressures such as hypoxia, immune surveillance, and therapy Clonal evolution drives disease progression and resistance, making single-target therapies less effective over time. Recognizing this diversity is

critical for designing combination and adaptive treatment strategies

Microenvironment: The Tumor's Habitat

The tumor microenvironment (TME) plays a central role in UC progression. It includes stromal cells, immune cells, extracellular matrix components, and signaling molecules. Cancer-associated fibroblasts, tumor-associated macrophages, and regulatory T cells

Journal of Cancer Research and Cellular Interventions (JCCRCI)

contribute to immune suppression and tumor growth.Rather than passive surroundings, these components actively shape tumor behavior

Disrupting this interaction through immunotherapy or stromal targeting—represents a promising therapeutic avenue.

Immune Evasion and Adaptation

Urothelial carcinoma is considered an immunogenic tumor, yet it frequently evades immune destruction. Mechanisms include

- Upregulation of immune checkpoint molecules (e.g., PD-L1)
- Loss of antigen presentation machinery
- Recruitment of immunosuppressive cells

Immune checkpoint inhibitors have revolutionized UC treatment, but responses are variable. This underscores the need to understand immune dynamics as part of a broader ecosystem rather than a single pathway

Metabolic Reprogramming: Fueling Survival

Cancer cells in UC undergo metabolic adaptations to survive in nutrient-poor and hypoxic conditions. Alterations in glycolysis, lipid metabolism, and oxidative phosphorylation support rapid proliferation and resistance. Metabolic crosstalk between tumor and stromal cells further complicates this landscape. Targeting metabolic vulnerabilities offers a novel, underexplored therapeutic direction.

Liquid Biopsy: Monitoring the Ecosystem in Real Time

Traditional tissue biopsies provide only a snapshot of the disease. Liquid biopsies—analyzing circulating tumor DNA (ctDNA), exosomes, and urinary biomarkers—enable real-time monitoring of tumor evolution**.** This approach aligns with the ecosystem model by capturing dynamic changes across the disease continuum, allowing for early detection of relapse and therapy adjustment

Clinical Implications of the Ecosystem Perspective

Personalized Treatment Strategies

Understanding UC as a heterogeneous ecosystem supports the move toward precision medicine. Molecular profiling can guide targeted therapies, immunotherapy selection, and combination regimens tailored to individual tumor characteristics.

Adaptive Therapeutic Approaches

Rather than fixed treatment protocols, adaptive strategies that evolve with tumor changes may improve outcomes

This includes sequential therapies, combination approaches, and real-time monitoring using biomarkers

Prevention and Early Detection

Environmental exposures (e.g., smoking, occupational carcinogens) interact with genetic susceptibility to influence UC development. The ecosystem model emphasizes prevention as part of disease management, alongside advances in non-invasive screening tools

Future Directions

- Integration of multi-omics (genomics, transcriptomics, metabolomics)
- Development of predictive biomarkers for treatment response
- Exploration of microbiome involvement in UC progression
- AI-driven models to simulate tumor ecosystem dynamics

Conclusion

Urothelial carcinoma is no longer adequately described as a localized epithelial malignancy. Viewing it as a complex, adaptive ecosystem provides a more comprehensive understanding of its behavior and therapeutic challenges. This paradigm shift encourages innovation in diagnostics, treatment, and disease monitoring, ultimately paving the way for more effective and personalized patient care.

References

1. Margulis, V.; Puligandla, M.; Trabulsi, E.J.; Plimack, E.R.; Kessler, E.R.; et al. Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma. J. Urol. 2019, 203, 690–698.
2. Loriot, Y.; Petrylak, D.P.; Kalebasty, A.R.; Fléchon, A.; Jain, R.K.; et al. TROPHY-U-01, et al Phase II Open-Label Study of Sacituzumab Govitecan in Patients with Metastatic Urothelial Carcinoma Progressing after Platinum-Based Chemotherapy and Checkpoint Inhibitors: Updated Safety and Efficacy Outcomes. Ann. Oncol. 2023, 35, 392–401.
3. Ricciardi, G.; Tralongo, P.; Fiorentino, V.; Germanà, E.; Ballato, M.; Giordano, W.G.; Pepe,

Journal of Cancer Research and Cellular Interventions (JCCRCI)

L.; et al. Roles for Epigenetic and Other Biomarkers in Upper Tract Urothelial Carcinoma Diagnosis and Surveillance. Curr. Probl. Cancer 2025, 58, 101222.

4. Bajorin, D.F.; Witjes, J.A.; Gschwend, J.E.; Schenker, M.; Valderrama, B.P.; Tomita, Y.; et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N. Engl. J. Med. 2021, 384, 2102–2114.
5. Céspedes Rodríguez, H.A.; Tello Duanes, D.A. Colovesical fistula, as a manifestation of cancer of the left colon: Case presentation. MedCrave Online J. Surg. 2022, 10, 49–50.
6. Koshkin, V.S.; Kumar, V.; Kline, B.; Escobar, D.; Aslam, M.; et al. Initial Experience with 68Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer. J. Nucl. Med. 2024, 65, 199–205.

.

Journal of Cancer Research and Cellular Interventions (JCCRCI)